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The unprecedented scale of the recent Ebola virus outbreak caused many to wonder whether this virus is
different, and raised concerns about how to contain the outbreak. Two recent studies published in Science
(Hoenen et al., 2015; Marzi et al., 2015) shed light on the subject and offer a new solution.The recent Ebola virus outbreak began in
December 2013. The first sequences of
the responsible virus (3 complete and 15
partial genomes) were obtained in March
2014 (Baize et al., 2014), when the
outbreak was limited to Guinea and
involved fewer than 100 cases. The next
sequence information was obtained in
June, of viruses isolated from 99 patients
in Sierra Leone (Gire et al., 2014). At that
time, the outbreak was confined to
Guinea, Sierra Leone, and Liberia and
had infected an estimated 500 people.
Now, Hoenen et al. (2015) describe se-
quences obtained from patients in Mali
in October and November 2014 when
the outbreak had expanded to 16,000
cases and the virus had been introduced
into Nigeria, Senegal, the United States,
Spain, and the United Kingdom.
Together, the three sequencing studies
provide distinct snapshots of a burgeon-
ing epidemic.
The original Baize study found that the
three separate 2014 patient samples
from Guinea were nearly identical to
each other: just 6 single nucleotide poly-
morphisms were found in the 18,959
nucleotide Ebola virus genome. Overall,
these sequences were 97% identical
to those isolated in prior outbreaks in the
Democratic Republic of Congo (DRC)
and Gabon, providing our first evidence
that the strain of Ebola virus inWest Africa
was distinct from those previously noted
in central Africa. Phylogenetic analysis
suggested that the 2014 Guinean Ebola
virus lineage evolved in parallel with the
DRC and Gabon viruses and may have
circulated undetected in West Africa for
some time.
Determination of the evolutionary origin
of the 2014 strain, and when it was phys-
ically introduced into West Africa, de-
pends on an accurate understanding ofthe rate at which mutations in Ebola virus
are fixed in nature, its ‘‘molecular clock.’’
The initial exploratory study sampled
three complete genomes, which may be
too few for accurate clock estimation.
The Gire study, performed a few months
later, provided a larger sample size and
estimated the molecular clock rate to
be 1.9 3 103 substitutions per site
per year (36 nucleotide differences per
Ebola virus genome per year). This rate
is substantially faster than previous esti-
mates of mutation rates in Ebola virus
(Biek et al., 2006; Carroll et al., 2013;
Walsh et al., 2005).
Now the most recent study has
compared samples collected in Mali in
October through November 2014 to those
reported in the Baize and Gire studies.
Hoenen et al. (2015) note 9–20 nucleotide
differences, suggesting that Ebola viruses
collected early and later in this outbreak
are 99.9% identical to each other. At the
protein level, only one to two amino acid
changes among three patients were
noted between Mali and Sierra Leone
samples, and four to six changes between
Mali and Guinea samples. The similarity
suggested a substitution rate of approxi-
mately 1 3 103 substitutions per site
per year (19 nucleotides per Ebola virus
genome per year), less than that sug-
gested by the Gire study.
Thus, these different snapshots of the
2014 virus have led to estimates of the
mutation rate between 1 and 2 3 103
(19–36 nucleotides per genome per year,
or 0.1%–0.2% of the genome differing
per year). These differences have led to
contrasting headlines in the popular
press. Note that these studies were per-
formed on different sets of sequences,
with different sample sizes, over different
time points and in different geographic
locations. The Gire study, which esti-Cell Host & Microbemated the highest substitution rate,
analyzed data from multiple time points
within individual patients. This analysis
may have beenmore likely to identify tran-
sient deleterious mutations, which are
only likely to circulate for a short time
period and may not become fixed in
populations.
Is understanding the precise value of
the clock important? An accurate repre-
sentation of evolutionary rates could
help determine when Ebola virus was
introduced into West Africa and link that
introduction to ecological factors in play
at the time. Understanding breeding cy-
cles, migration patterns, human behavior,
or weather events that led to establish-
ment of the virus in West Africa could
help us predict future movement of
Ebola or many of the other human patho-
genic viruses carried by similar reservoir
species.
A more pragmatic view is that these
debated differences in molecular clock
are all within the range of what has been
previously noted for other RNA viruses
(Duffy et al., 2008) such that they can all
be thought of as rapidly evolving. Further,
all 2014 sequences from West Africa in
these three different studies are >99.9%
identical at the nucleotide level. However,
this raises another question. Given that
RNA virus replication is error-prone, why
do we not see more phenotypic variation
among Ebola viruses? Why is the 1976
virus seemingly so similar to that from
2014? One hypothesis is that Ebola virus
is not subject to much selective pres-
sure/immune surveillance in its natural
reservoir. Another hypothesis is that it is
instead subject to very strong selective
pressure in its reservoir, but that pressure
drives purifying selection (of very little
change), rather than positive selection
(change in a certain direction).17, May 13, 2015 ª2015 Elsevier Inc. 545
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mutations are noted between this West
African strain (now termed Makona) and
Central African Ebola variants. Many of
these mutations occur in regions of
the proteome thought to be structurally
flexible and/or previously known to be
variable in sequence. One mutation
could certainly alter virulence, but the
effect of any of these mutations can
only be determined by functional assays.
Purifying selection may also operate
on the protein level of the virus itself.
Ebola virus only has seven genes. Each
of its gene products, except perhaps
secreted versions of the glycoprotein,
are essential, and many are multifunc-
tional. One protein, VP40, assumes at
least three different assemblies for three
distinct and essential functions. The
requirement for that single polypeptide
to adopt three unique tertiary and qua-
ternary structures means that it may
encode comparatively fewer amino acids
tolerant of mutation.
For additional perspective, one may
also note that the scale of variation among
sequences of Ebola viruses is dwarfed,
by orders of magnitude, by the scale of
variation among sequences of HIV-1 and
hepatitis C. Ebola virus causes acute
infection and is cleared, or the patient per-
ishes, within weeks. By contrast, HIV-1
and hepatitis C cause chronic infections
that persist in humans for decades and
are constantly subject to error-prone
replication and selective immune pres-
sure from the host. The extreme chal-
lenges in developing immunogens for
HIV-1 that accurately reflect the array of
circulating HIV-1 sequences likely do not
apply to Ebola virus.
For public health, the key question is
how to generate a vaccine to protect
against Ebola virus. Fortunately, multiple
candidate vaccines have shown promise
in non-human primate models of infec-
tion. Many of these vaccines function by
displaying the Ebola virus surface glyco-
protein (GP) on carrier virus particles
that differ in shape, presentation of GP,
and ability to replicate. Such differences
can lead to different immune responses
and correlates of protection by each
vaccine. In one vaccine in clinical trials,
the carrier is replication-competent vesic-
ular stomatitis virus (VSV). In another
vaccine candidate, Ebola virus GP is
displayed on a chimpanzee adenovirus.546 Cell Host & Microbe 17, May 13, 2015 ª2The adenovirus shot can be followed by
boost of Ebola GP displayed on a vaccinia
virus-like particle.
In a recent paper by Marzi et al. (2015),
a new strategy was described in which
Ebola GP is displayed on a natural
Ebola virus particle that has been engi-
neered to be replication defective.
A chief difference between this vaccine
and others is that this one is a (nearly)
whole virus vaccine: the presence of
the other viral proteins and viral nucleic
acid could trigger a broader and more
robust immune response than vaccina-
tion with GP as the only viral antigen.
Further, this particle mimics the shape,
GP display, and spacing of natural Ebola
virus with fidelity.
How was this particle made replication
defective? The genome of natural Ebola
virus encodes a protein, VP30, which
is an essential transcription factor. This
vulnerability was exploited to create a
version of the virus suitable for use
outside of a BSL-4 containment facility
(Halfmann et al., 2008). Ebola virus
deleted for the VP30 gene can be repli-
cated only in cells engineered to stably
express the VP30 protein but will not
replicate in any other cell, such as
those of the researcher, for example.
As the DVP30 genome is incorporated
into filovirus particles that are capable
of entering host cells, this system has
been used as a laboratory model for
functional analysis of the ebolavirus life
cycle in vitro. In vivo, immunization of
mice and guinea pigs with DVP30 parti-
cles caused no illness and protected
them from lethal doses of Ebola virus
(Halfmann et al., 2009). This year, the
team demonstrated that vaccination
with DVP30 also protected nonhuman
primates from lethal Ebola virus chal-
lenge (Marzi et al., 2015). The vaccine
elicited both T cell and antibody re-
sponses, and because this is a (nearly)
whole-virus vaccine, antibodies were
elicited against the surface GP as well
as the internal nucleoprotein NP and
matrix protein VP40.
Immunization of a particle that so
closely resembles the natural virus may
raise eyebrows, although in animal
studies this particle has not altered its
behavior or acquired the missing gene.
Whole-virus vaccines (either inactivated
or attenuated) have previously been
used in humans against influenza, small-015 Elsevier Inc.pox, measles, and mumps. Note that
Ebola virus has no integrase in its life-
cycle and has no segments to reassort,
as does influenza. However, to alleviate
the possibility of something unexpected
happening, the team sought to inactivate
the DVP30 particles so that they are
replication defective whether or not
VP30 is present. They found that hydro-
gen peroxide treatment of the DVP30
particles inactivates them but retains
their immunogenicity (Marzi et al., 2015).
An interesting and potentially useful
feature of this vaccine strategy is that
it involves a filovirus particle. Hence, vac-
cine recipients probably won’t have prior
immunity against the carrier virus itself,
which can prevent the desired immune
responses. Use of a filovirus particle
does not ‘‘use up’’ that particle carrier
in a vaccinee’s potential immune portfo-
lio: many of the same carrier viruses are
being considered for vaccines against
different viruses.
Multiple types of Ebola virus vaccines
have now been shown to work well in
nonhuman primate models. The next
questions are: will they work in humans?
How long will immunity last? If Ebola
virus breaks out again in 10 years, will
vaccinees still be immune? Only time
will tell.
The wealth of information and technol-
ogy moving forward offers hope that
we will not have another crisis quite like
2014—for this virus, anyway. We are,
however, much less prepared for other
filoviruses and co-circulating pathogens.
Surveillance, vigilance, and maintaining
progress are key.REFERENCES
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